Paracelsian Announces Management Changes
ITHACA, N.Y., Sept. 19 /PRNewswire/ -- Paracelsian, Inc. (Nasdaq:PRLN) announced today the appointment of Thomas G. Tachovsky, Ph.D., as acting Chief Executive Officer and President. In this capacity, Dr. Tachovsky will be responsible for managing all the activities of the Company.
The Company also announced that Keith A. Rhodes has tendered his resignation as Chairman, President and Chief Executive Officer. ``The Board of Directors is extremely grateful for Keith's leadership in arranging funding of the Company in the past two years,'' said Mr. Theodore Nikolis, the Company's new Chairman. While Mr. Rhodes remains a Director of the Company, he plans to remain actively involved in the arrangement of financial support for mid-sized companies.
Dr. Tachovsky joins the Company from Protyde Pharmaceuticals, Inc. of Watertown, Mass., a company which he both founded and directed and at which he was Executive Vice President of Research and Development. Previously, Dr. Tachovsky has held a series of executive positions with consulting firms specializing in strategic issues related to biopharmaceutical and health care industries.
``Dr. Tachovsky brings more than 20 years experience in the management and business development of pharmaceutical and biomedical technology companies that we believe will be extremely valuable to Paracelsian's efforts,'' said Mr. Nikolis.
Dr. Tachovsky earned a Ph.D. in Microbiology from the University of Rochester, School of Medicine, Rochester, N.Y. He also holds a M.S. degree in Management from Lesley College, Cambridge, Mass. and a B.S. in Biology from Gonzaga University, Spokane, Wash.
Paracelsian, Inc. also appointed Ms. Karen Jackson as Vice President and Dr. Lee Henderson as Vice President. Dr. Henderson is serving as a non-compensated corporate officer.
Paracelsian, Inc. is a biopharmaceutical company whose core technology consists of proprietary signal transduction assays including immuno- and cell-based assays. |
